Jentadueto (Linagliptin/Metformin)
Type 2 Diabetes
ApprovedCommercial
Key Facts
About Yuhan
Founded in 1926, Yuhan Corporation is one of South Korea's most established and innovative pharmaceutical companies, operating with a dual focus on a profitable commercial business and a cutting-edge R&D pipeline. The company has achieved significant milestones, including the successful development and out-licensing of its EGFR inhibitor, lazertinib, to Janssen, and the commercialization of its leading diabetes franchise. Yuhan's strategy is built on internal R&D in oncology and immunology, strategic in-licensing, and global partnerships to expand its reach beyond the Korean market.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Mounjaro) | Eli Lilly | Approved |
| Orforglipron | Eli Lilly | Phase 3 |
| Trulicity (dulaglutide) | Eli Lilly | Approved |
| Forxiga | AstraZeneca | Approved |
| siRNA GalXC-GYS2 | Novo Nordisk | Phase 1 |
| Amylin/semaglutide combination | Novo Nordisk | Phase 3 |
| Lipaglyn | Zydus Lifesciences | Approved |
| LBS-009 | Belite Bio | Preclinical |
| Nesina (Alogliptin) | Yuhan | Approved |
| Metformin & Combinations | Ipca Laboratories | Commercial |
| GSBR-1290 | Structure Therapeutics | Phase 2 |
| Metformin | Granules India | Approved/Commercial |